ClinicalTrials.gg
RecruitingNCT06845709Updated Feb 25, 2025

Effects of Otago and Gaze Stabilization Exercises on Balance, Gait and QOL in Elderly Stroke Patients

An interventional study of gaze stabilization exercise and otago exercise in Balance; Distorted, Gait, Hemiplegic and Quality of Life, sponsored by Riphah International University. Recruiting at 1 site in Pakistan. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-25.

Sponsored by Riphah International University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Sep 2024, registered Feb 2025).
  • Started Sep 2024; still recruiting 2 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
All
01

Study summary

To compare effects of otago exercises and Gaze stabilization exercises on Balance, gait and quality of Life in elderly stroke patients

Read the detailed description

Study design will be a randomized clinical trial . Total 46 stroke patients will be recruited from Riphah Rehabilitation center and General hospital, Lahore by using non-probability convenience sampling technique. Patients will be randomized and allocated into two intervention groups based on inclusion and exclusion criteria. Patients in group A will receive Gaze Stabilization Exercises with conventional baseline treatment and group B patients will receive Otago Exercises with conventional baseline treatment. Patients will receive treatment of 40 minutes per session for 5 days a week for 8 weeks. Berg Balance Scale, Dynamic Gait Index and Stroke specific quality of life will be used as assessment tools. Data will be analyzed by using SPSS 26 version.

02

Conditions studied

  • Balance; Distorted
  • Gait, Hemiplegic
  • Quality of Life

Keywords

  • Balance; Distorted
  • Gait, Hemiplegic
  • Quality of Life
03

In context

Gait Disorders, Neurologic

339 studies on the registry are indexed under Gait Disorders, Neurologic; 55 are open to participants now.

This study's planned enrollment of 46 is above the median of 30 across 255 interventional studies indexed under Gait Disorders, Neurologic.

Browse Gait Disorders, Neurologic studies →

Lead sponsor

Riphah International University is the lead sponsor of 2,176 studies on the registry; 637 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Had ischemic or haemorrhagic stroke ≤6 months
  • Berg Balance Scale (BBS) score between 35 and 45
  • Dynamic Gait Index score between 11 and 19
  • Mini-mental status exam scores > 24

Exclusion criteria

Exclusion Criteria:

  • Participants with severe vision or hearing impairment
  • Neurological disorders including epilepsy, Alzheimer's disease, vertigo, Parkinson disease, and stroke, muscular disorders which limit functional activity (OA, RA, etc)
  • Medications that affect balance, severe cardiovascular conditions, recent lower limb injury or surgery
  • Peripheral vestibular disorder
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    gaze stabilization exercise

    Patients in group A will receive Gaze Stabilization Exercises with conventional baseline treatment

    Other: gaze stabilization exercise

  • Active comparator
    otago exercise

    Patients in group B will receive Otago Exercises with conventional baseline treatment.

    Other: otago exercise

Interventions

  • Othergaze stabilization exercise

    Patients in group A will receive Gaze Stabilization Exercises with conventional baseline treatment

  • Otherotago exercise

    group B patients will receive Otago Exercises with conventional baseline treatment

06

What researchers measure

Primary outcomes

  1. Berg Balance Scale

    Berg Balance Scale Most reliable balance measuring tools for people suffered from stroke known as Berg Balance Scale. There are 14 questions in it, which aims at testing balance while sitting, standing, or performing specific movements. The total score on the Berg Balance Scale ranges from 0 to 56. 41-56: Have good balance and are at a low risk of falling. 21-40: Individuals have an increased risk of falling and may benefit from interventions to improve balance. 0-20: Individuals in this range have a significant balance impairment and are at a high risk of falling, requiring more intensive intervention and possibly assistance with mobility. Most of researches supported the validity and reliability of the BBS especially with stroke patients with high interclass correlation coefficients (ICCs) 0. 90

    Time frame: 10 months

  2. Dynamic Gait Index

    Dynamic Gait Index A tool for assessing gait, balance and fall risk in stroke patients is known as Dynamic Gait Index. It involves eight generic movements that are representative of common gait problems like turning the head while walking, stepping over an object, or changing speed. Consist of total 0-24 score . Between 22-24: Normal and \< 19: Abnormal. Scores below 19 are indicative of gait dysfunction . Dynamic Gait Index validity is 0. 90. The overall reliability was high (overall intra-class correlation coefficient = .96

    Time frame: 10 months

  3. Stroke-Specific Quality of Life (SS-QOL)

    Stroke-Specific Quality of Life (SS-QOL) is a specially developed tool for estimating the quality of life of stroke survivors. SS-QOL scale consists of 49 items, comprises 12 domains include Energy, Family Roles, Language, Mobility, Mood, Personality, Self-care, Social Roles, Thinking, Upper Extremity Function, Vision, and Work/Productivity. Each item is scored on a 5-point Likert scale. where 1 indicates the most severe impairment and 5 indicates no impairment. The total score can range from 49 to 245, with higher scores representing better quality of life. In the SS-QOL domains, the Cronbach's alpha coefficients are generally provided with values of between 0. 73 and 0. 96. Concurrent validity was high with r = 0.94-0.95

    Time frame: 10 months

07

Study locations

1 of 1 sites recruiting
  • Riphah International University
    Islamabad, Fedral 44000, Pakistan
    • zeest Hashmi, MS NMPT · Contact · 03224655851
    • Imran Amjad, PhD · Contact · Imran.amjad@riphah.edu.pk · 03324390125
    • Hifza Riaz, MS NMPT · Principal investigator
    Recruiting
08

References and documents

Publications

  • Di Vincenzo O, Luisi MLE, Alicante P, Ballarin G, Biffi B, Gheri CF, Scalfi L. The Assessment of the Risk of Malnutrition (Undernutrition) in Stroke Patients. Nutrients. 2023 Jan 29;15(3):683. doi: 10.3390/nu15030683. PubMed 36771390 ↗
  • Mead GE, Sposato LA, Sampaio Silva G, Yperzeele L, Wu S, Kutlubaev M, Cheyne J, Wahab K, Urrutia VC, Sharma VK, Sylaja PN, Hill K, Steiner T, Liebeskind DS, Rabinstein AA. A systematic review and synthesis of global stroke guidelines on behalf of the World Stroke Organization. Int J Stroke. 2023 Jun;18(5):499-531. doi: 10.1177/17474930231156753. Epub 2023 Mar 1. PubMed 36725717 ↗
  • Sim J, Shin C. Two stroke education programs designed for older adults. Geriatr Nurs. 2024 Jan-Feb;55:105-111. doi: 10.1016/j.gerinurse.2023.10.014. Epub 2023 Nov 17. PubMed 37979469 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06845709
Responsible party
Sponsor
First posted
Feb 25, 2025
Start date
Sep 1, 2024
Primary completion
Mar 1, 2025 (estimated)
Completion
Apr 15, 2025 (estimated)
Last update
Feb 25, 2025

Study contacts

Zeest Hashmi, MS NMPT
Contact
zeesthashmi1@gmail.com
03224655851
Imran Amjad, PhD
Contact
Imran.amjad@riphah.edu.pk
03324390125
Dr.Zeest Hashmi, MSNMPT
principal investigator · Riphah International University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion